MF Scanlon

1.6k total citations
40 papers, 1.2k citations indexed

About

MF Scanlon is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, MF Scanlon has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in MF Scanlon's work include Pituitary Gland Disorders and Treatments (17 papers), Growth Hormone and Insulin-like Growth Factors (12 papers) and Adrenal and Paraganglionic Tumors (6 papers). MF Scanlon is often cited by papers focused on Pituitary Gland Disorders and Treatments (17 papers), Growth Hormone and Insulin-like Growth Factors (12 papers) and Adrenal and Paraganglionic Tumors (6 papers). MF Scanlon collaborates with scholars based in United Kingdom, Belgium and United States. MF Scanlon's co-authors include P. S. Sharp, Stephen Franks, Davinia White, Michael Reed, H. D. Mason, D. W. POLSON, D. Kiddy, Carlo Ferrari, E. Ciccarelli and Jeffrey S. Davies and has published in prestigious journals such as The Lancet, The Journal of Clinical Endocrinology & Metabolism and European Heart Journal.

In The Last Decade

MF Scanlon

39 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
MF Scanlon United Kingdom 16 755 306 291 212 141 40 1.2k
Bernard Corenblum Canada 21 607 0.8× 238 0.8× 468 1.6× 250 1.2× 102 0.7× 54 1.2k
Ivica Lazúrová Slovakia 22 554 0.7× 365 1.2× 241 0.8× 127 0.6× 129 0.9× 111 1.4k
C Jaffiol France 17 597 0.8× 425 1.4× 122 0.4× 122 0.6× 131 0.9× 104 1.3k
Ron S. Newfield United States 20 539 0.7× 208 0.7× 115 0.4× 147 0.7× 70 0.5× 61 1.3k
Geneviève Plu‐Bureau France 13 555 0.7× 122 0.4× 220 0.8× 158 0.7× 63 0.4× 27 1.5k
Peter Hornnes Denmark 20 549 0.7× 447 1.5× 227 0.8× 283 1.3× 80 0.6× 56 1.5k
Nikolaos Pontikides Greece 19 686 0.9× 102 0.3× 240 0.8× 107 0.5× 105 0.7× 33 1.1k
Maria Creatsa Greece 20 420 0.6× 120 0.4× 387 1.3× 267 1.3× 68 0.5× 61 1.2k
Dorothy I. Shulman United States 20 1.0k 1.3× 358 1.2× 188 0.6× 68 0.3× 93 0.7× 69 1.9k
M. D. G. Gillmer United Kingdom 21 232 0.3× 329 1.1× 153 0.5× 195 0.9× 69 0.5× 63 1.5k

Countries citing papers authored by MF Scanlon

Since Specialization
Citations

This map shows the geographic impact of MF Scanlon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MF Scanlon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MF Scanlon more than expected).

Fields of papers citing papers by MF Scanlon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MF Scanlon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MF Scanlon. The network helps show where MF Scanlon may publish in the future.

Co-authorship network of co-authors of MF Scanlon

This figure shows the co-authorship network connecting the top 25 collaborators of MF Scanlon. A scholar is included among the top collaborators of MF Scanlon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with MF Scanlon. MF Scanlon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sever, Peter, Margaret F. Prescott, Ajay Gupta, et al.. (2012). Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). European Heart Journal. 33(23). 2970–2979. 12 indexed citations
2.
Francis, Karl, et al.. (2006). Complement C5a inhibits the secretion of macrophage migration inhibitory factor (MIF) in anterior pituitary cell lines. 11. 1 indexed citations
3.
Maiter, Dominique, Roger Abs, Gudmundur Johannsson, et al.. (2006). Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. European Journal of Endocrinology. 155(2). 253–260. 22 indexed citations
4.
Francis, Karen, et al.. (2005). Complement C5a receptors are expressed throughout the anterior pituitary gland. 2 indexed citations
5.
Lane, Helen W., et al.. (2005). Cushing's syndrome in pregnancy: a case report. Virology Journal. 6. 120–120. 1 indexed citations
6.
Banerjee, Indraneel, et al.. (2005). Are Factors at Diagnosis of Growth Hormone Deficiency in Childhood Associated with Persistence of Growth Hormone Deficiency into Adult Life?. Journal of Pediatric Endocrinology and Metabolism. 18(10). 943–7. 2 indexed citations
7.
Lewis, B. M., Karen Francis, Philippe Gasque, MF Scanlon, & J. Ham. (2002). Functional complement C3a receptors in the rat pituitary gland. 3. 1 indexed citations
8.
George, Lindsay, et al.. (2000). Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clinical Endocrinology. 53(5). 595–599. 19 indexed citations
9.
Davies, Jeffrey S., RA Anderson, G Ellis, et al.. (2000). The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. European Journal of Endocrinology. 142(3). 254–262. 98 indexed citations
10.
11.
Davies, J. S., et al.. (1998). Hypokalaemia during insulin‐induced hypoglycaemia in hypopituitary adults with and without growth hormone deficiency. Clinical Endocrinology. 49(2). 217–220. 7 indexed citations
12.
Ferrari, Carlo, Roger Abs, J. S. Bevan, et al.. (1997). Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clinical Endocrinology. 46(4). 409–413. 110 indexed citations
13.
Webster, Jonathan, G. Piscitelli, A D’Alberton, et al.. (1993). The efficacy and tolerability of long‐term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clinical Endocrinology. 39(3). 323–329. 50 indexed citations
14.
Webster, Jonathan, G. Piscitelli, Anna Polli, et al.. (1992). Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. Clinical Endocrinology. 37(6). 534–541. 48 indexed citations
15.
Kiddy, D., P. S. Sharp, Davinia White, et al.. (1990). DIFFERENCES IN CLINICAL AND ENDOCRINE FEATURES BETWEEN OBESE AND NON‐OBESE SUBJECTS WITH POLYCYSTIC OVARY SYNDROME: AN ANALYSIS OF 263 CONSECUTIVE CASES. Clinical Endocrinology. 32(2). 213–220. 285 indexed citations
16.
Diéguez, Carlos, M. D. Page, John R. Peters, & MF Scanlon. (1988). Growth Hormone and Its Modulation. Journal of the Royal College of Physicians of London. 22(2). 84–91. 6 indexed citations
17.
Hall, R., C. J. Roberts, Gerald A. Coles, et al.. (1988). The Impact of Guidelines in Clinical Outpatient Practice. Journal of the Royal College of Physicians of London. 22(4). 244–247. 9 indexed citations
18.
Evans, Peter J., J S Woodhead, Ian Weeks, & MF Scanlon. (1987). CIRCULATING TSH LEVELS MEASURED WITH AN IMMUNOCHEMILUMINOMETRIC ASSAY IN PATIENTS TAKING DRUGS INTERFERING WITH BIOCHEMICAL THYROID STATUS. Clinical Endocrinology. 26(6). 717–721. 10 indexed citations
19.
Fowkes, F.G.R., R Hall, MF Scanlon, et al.. (1986). Trial of strategy for reducing the use of laboratory tests.. BMJ. 292(6524). 883–885. 47 indexed citations
20.
Diéguez, Carlos, Vanessa Jordan, P. M. Harris, et al.. (1986). Growth hormone responses to growth hormone-releasing factor (1–29) in euthyroid, hypothyroid and hyperthyroid rats. Journal of Endocrinology. 109(1). 53–56. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bernard Corenblum Breakdown of academic impact, for papers by Ivica Lazúrová Breakdown of academic impact, for papers by C Jaffiol Breakdown of academic impact, for papers by Ron S. Newfield Breakdown of academic impact, for papers by Geneviève Plu‐Bureau Breakdown of academic impact, for papers by Peter Hornnes Breakdown of academic impact, for papers by Nikolaos Pontikides Breakdown of academic impact, for papers by Maria Creatsa Breakdown of academic impact, for papers by Dorothy I. Shulman Breakdown of academic impact, for papers by M. D. G. Gillmer
Rankless by CCL
2026